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Abstract
Purpose Rifampin combination therapy plays an impor-
tant role in the management of staphylococcal peripros-
thetic joint infection (PJI). However, the emergence of
rifampin resistance is a feared complication. We retro-
spectively analysed predetermined potential risk factors in
patients with rifampin-resistant staphylococcal PJI in a
multicentre case–control study.
Methods Cases (n = 48) were defined as PJI caused by
rifampin-resistant staphylococci. Rifampin-susceptible
controls (n = 48) were matched for microorganism and
type of prosthetic joint. Uni- and multivariable conditional
logistic regression analyses were performed to estimate
odds ratios (OR) with 95 % confidence intervals (95 %
CI).
Results Forty-eight cases (31 men; median age 67 years;
age range 39–88 years) with hip- (n = 29), knee-
(n = 13), elbow- (n = 4), shoulder- (n = 1) or ankle-PJI
(n = 1) were enrolled in the study. Staphylococcus aureus
and coagulase-negative staphylococci were isolated in ten
and 38 episodes, respectively. Most of the cases (n = 44,
92 %) had a previous PJI, and 93 % (n = 41) of these had
been treated with rifampin. There was an independent
association of emergence of rifampin resistance with male
sex (OR 3.6, 95 % CI 1.2–11), C3 previous surgical revi-
sions (OR 4.7, 95 % CI 1.6–14.2), PJI treatment with high
initial bacterial load (inadequate surgical debridement,
\2 weeks of intravenous treatment of the combination
medication; OR 4.9, 95 % CI 1.6–15) and inadequate
rifampin therapy (OR 5.4, 95 % CI 1.2–25).
Conclusions Based on our results, extensive surgical
debridement and adequate antibiotic therapy are needed to
prevent the emergence of rifampin resistance.
Keywords Rifampin  Periprosthetic joint infection 
Staphylococci  Antibiotic resistance  Case–control study
Introduction
During the last 20 years, rifampin has been increasingly used
in implant-associated staphylococcal infections [1–9].
Microorganisms grow and persist as a biofilm on the implant
surface and, consequently, such infections are difficult to
eradicate. The definite cure of biofilm infections requires
adequate surgical debridement and prolonged antimicrobial
therapy [10]. Rifampin is active against such infections
because it has a low minimal bactericidal concentration
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against Staphylococcus aureus and coagulase-negative
staphylococci (CNS) in the stationary phase of growth [11–
14]. It has been shown to cure experimental implant-asso-
ciated staphylococcal infections in animal models and has
been found to be more efficacious than standard therapy in
observational studies as well as in a controlled trial of
patients with orthopaedic device-associated infection [1, 3–
6, 15–19]. However, when given as monotherapy, the
emergence of resistance is frequent. Resistance occurs by a
single-step mutation in the DNA-dependent rRNA poly-
merase (alterations in the rpoB gene) with a frequency of
10-8 [20–24]. Therefore, rifampin should always be used in
combination with another active antibiotic. There are addi-
tional potential risk factors for the emergence of resistance.
Patients with a compromised skin barrier (open wound, sinus
tract or postoperative drainage) who are treated with rifam-
pin are potentially at risk for acquiring a superinfection
caused by selected rifampin-resistant skin bacteria. Fur-
thermore, the risk for emergence of rifampin resistance is
increased if the bacterial load at the start of treatment is high,
i.e. as in the case of an abscess. This situation may arise if
debridement surgery and/or initial treatment is not per-
formed with a concomitant intravenous antibiotic.
The aim of this study was to analyze potential risk
factors for the emergence of rifampin resistance in a ret-
rospective case–control study of patients with staphylo-
coccal periprosthetic joint infection (PJI). Such data would
allow strategies to be developed for the prevention of
rifampin resistance.
Methods
Study design and population
In this multicentre case–control study, factors associated
with rifampin resistance in patients with staphylococcal PJI
were analysed. Patients suffering from staphylococcal PJI
between January 2001 and April 2010 were retrospectively
included in the study. Data from clinical, demographic,
microbiological, antimicrobial treatment and surgical
intervention from primary implantation and all revisions
were summarized with a standardized case report form
(CRF) by an infectious diseases service physician of each
clinic. One author (YA) analysed all data from the different
medical centers as an independent person.
Cases were identified in the laboratory registers of all
participating study centres. In two centres (Clinic Schulth-
ess, Zurich; University Clinic of Liestal) cases were also
crosschecked for completeness with information obtained
from a prospective database of the Infectious Diseases
Consultation Service and from the prospective Orthopaedic
Prosthetic Joint Cohort database. Inclusion criteria for a case
patient were (1) age C16 years and (2) PJI during the period
from January 2001 and April 2010 that was caused by
S. aureus or CNS resistant to rifampin, as determined by
microdilution or the strip test (E-Test). The exclusion crite-
rion was an incomplete medical chart, i.e. no complete
information about the preceding PJI (referring hospital, no
storage of patient chart, incomplete data on antibiotic and
surgical treatment). In the whole study population, one case
was matched with one control for the infecting agent
(S. aureus or CNS) and the affected joint (hip, knee, elbow,
ankle, shoulder). Control patients with a susceptible staph-
ylococcal PJI were all identified from the database of the
Infectious Diseases Service of the Orthopaedic Center
Schulthess in Zurich. This centre has a complete database
excluding a selection bias of the controls.
Definitions
Prosthetic joint infection was diagnosed if one or more of
the following criteria were fulfilled: (1) visible purulence
of a preoperative aspirate or intraoperative periprosthetic
tissue (as determined by the surgeon), (2) presence of a
sinus tract communicating with the prosthesis, (3) micro-
bial growth in a preoperative joint aspirate, intraoperative
periprosthetic tissue or sonication fluid of the removed
implant or (4) synovial fluid with [1,700 leukocytes/ll
or [ 65 % granulocytes [25–27]. These diagnostic criteria
are well accepted and have been used in several previous
studies of PJI [2, 28].
Inadequate rifampin treatment was defined as (1)
monotherapy, (2) empiric rifampin combination with a
narrow-spectrum antibiotic (e.g. clindamycin or flucloxa-
cillin) or (3) combination therapy with an oral antibiotic
with low bioavailability (e.g. oral betalactam) or an inad-
equate low dose.
Potential risk factors for emergence of rifampin
resistance
We looked for documentation of the following potential
risk factors for rifampin resistance: (1) repeated previous
surgical revisions, (2) previous PJI treated with any type of
antibiotics, (3) previous rifampin therapy, (4) previous
inadequate rifampin treatment, (5) prolonged wound dis-
charge ([14 days) or sinus tract (6) expected high bacterial
load at start of antibiotic treatment, as defined by \2 weeks
of initial intravenous therapy and/or no surgical debride-
ment surgery.
Statistical analysis
In this multicentre retrospective case–control study we
matched one case with one control for the following two
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groups: (1) infecting agent (S. aureus or CNS) and (2)
localization of PJI (hip, knee, elbow, ankle, shoulder).
Associations between rifampin resistance and clinical and
demographic characteristics were assessed by univariable
and multivariable conditional logistic regression analyses.
For statistical analysis, we used Stata software ver. 10.1
(StataCorp, College Station, TX).
Characteristics/factors studied were age at infection,
sex, underlying joint disease, time to infection from last
surgical revision, microbiological characteristics of infec-
tion (mono- or polymicrobial infection, methicillin resis-
tance), previous number of revisions, previous history of
PJI treated with antibiotics, previous exposure to rifampin
(adequate or inadequate), high density of staphylococci at
start of antibiotic treatment (no surgical debridement or
initial intravenous therapy for less than 2 weeks), sinus
tract or wound discharge. The multivariable models were
based on factors with P values of B0.1 in the univariable
analyses.
The study protocol was approved by the Institutional
Review Boards of the respective institutions.
Results
Baseline characteristics of the 48 cases with rifampin-
resistant staphylococcal PJI
Baseline characteristics of the 48 patients with rifampin-
resistant staphylococcal PJI are summarized in Table 1.
The median age of these patients was 67 years (range
39–88 years), and 31 (65 %) were male. Infected devices
were hip- (n = 29, 60 %) knee- (n = 13, 27 %), elbow-
(n = 4, 8 %) and ankle- and shoulder-prostheses (one
each, 2 %). The indications for joint replacement were
osteoarthritis (34 patients, 71 %), rheumatic disorders (4,
8 %) and trauma (10, 21 %). Ten cases of rifampin-resis-
tant PJI were caused by S. aureus and 38 by CNS. Of the
staphylococcal isolates resistant to rifampin, 31 (65 %) of
the CNS isolates, but none of the S. aureus isolates, were
methicillin-resistant. Most of the patients had previous
revision surgery, such as debridement or exchange of the
prosthesis due to any reason (median revision surgery 3.1,
range 0–25). The median time to infection after the last
surgical procedure was 5.1 months.
Almost half of the patients (46 %) had a previous sinus
tract or a prolonged wound discharge of [14 days due to
PJI. Most of the patients with a previous PJI were treated
with antibiotics (n = 44, 92 %), including rifampin
(n = 41, 85 %). In 25 of 41 patients (61 %), previous
rifampin therapy was correctly given. However, four
patients had either monotherapy (n = 1) or a combination
with an inactive drug (n = 3). Seven patients were
previously treated with a rifampin combination for a cul-
ture-negative PJI, and seven other patients had a combi-
nation either with an underdosed drug (n = 3) or an oral
betalactam (n = 4). In 34 patients (71 %), intravenous
antimicrobial treatment was either shorter than 2 weeks
(n = 12) and or the patients did not receive surgical
debridement (n = 22) at the start of therapy.
Demographic and clinical variables affecting the risk
of emergence of rifampin resistance according
to univariable and multivariable logistic regression
analyses
Table 2 shows the results of univariable and multivariable
logistic regression analyses. In the univariable model, male
sex and multiple (C3) previous surgical revisions were
significant risk factors, as well as previous PJI with a sinus
tract or prolonged wound discharge ([14 days) and any
previous antibiotic treatment, especially with rifampin.
Previous rifampin treatment is a risk factor for the emer-
gence of rifampin resistance in general [odds ratio (OR)
7.8], and even more so if given in an inadequate manner
(OR 10.2). Finally, a short initial intravenous treatment
(\2 weeks) and lack of surgical debridement were also
significant risk factors.
Analysis using a multivariable model (Table 2) revealed
the following independent risk factors: (1) male sex (OR
3.6), (2) C3 surgical revisions (OR 4.7), (3) previous PJI
treated with rifampin in inadequate (OR 5.4) manner and
(4) presumably high bacterial load at start of the antibiotic
treatment (OR 4.9).
Discussion
In this retrospective case–control study, we found an
independent association between the emergence of rifam-
pin resistance and male sex, C3 previous surgical revi-
sions, rifampin treatment without surgical debridement or
\2 weeks of initial intravenous antibiotic therapy with an
concomitant drug, as well as inadequate rifampin therapy
as defined in the ‘‘Methods’’.
With increasing rifampin resistance, fewer patients with
PJI would be able to benefit from orthopaedic implant
retention. In most countries, spontaneous resistance of
staphylococci to rifampin is rare. In Spain, in a survey
carried out between 1999 and 2008, 0.26 % of the methi-
cillin-sensitive Staphylococcus aureus (MSSA) and 3.26 %
of the methicillin-resistant S. aureus (MRSA) isolates were
resistant to rifampin [29]. However, if rifampin is inade-
quately used, resistance may emerge due to a single-step
point mutation [20, 22–24, 29]; thus, there is always
the potential for rifampin resistance to emerge rapidly [12].
Rifampin resistance in PJI 433
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Table 1 Baseline characteristics of 96 patients at time of periprosthetic joint infection with rifampin-resistant staphylocci
Characteristics Cases (n = 48) Controls (n = 48) P valuea
Current PJI
Age at hospital admission, median years (range) 67 (39–88) 67 (39–85) 0.39e
Male gender 31 (65 %) 17 (35 %) 0.004
Localization of joint prosthesis Matching
Hip 29 (60.4 %) 29 (60.4 %)
Knee 13 (27.1 %) 13 (27.1 %)
Shoulder 1 (2.1 %) 1 (2.1 %)
Elbow 4 (8.3 %) 4 (8.3 %)
Ankle 1 (2.1 %) 1 (2.1 %)
Underlying joint disorder 0.074f
Primary osteoarthritis 34 (70.8 %) 37 (77.1 %)
Rheumatic osteoarthritis 4 (8.3 %) 8 (16.7 %)
Posttraumatic osteoarthritis 10 (20.8 %) 3 (6.3 %)
Microorganism
S. aureus 10 (20.8 %) 10 (20.8 %) Matching
Coagulase-negative staphylococci 38 (79.2 %) 38 (79.2 % Matching
Polymicrobial infections 3 (6.3 %) 6 (12.5 %) 0.49f
Microbial resistance
Rifampin resistance 48 (100 %) 0 (0 %) \0.001f
Methicillin resistance 31 (64.6 %) 28 (58.3 %) 0.53
Time from last surgical revision to infection (months) 5.1 5.7 0.18e
Previous surgical revisions, median (range) 3 (0–11) 1 (0–25) 0.002e
C3 revisions 32 13
Previous PJI 44 (91.7 %) 30 (62.5 %) 0.001f
Clinical signs
Sinus tract, wound discharge 22 (45.8 %) 12 (25 %) 0.054f
Sinus tract and/or 14 7
Wound discharge ([14 days) 13 6
Treatment
Treated with any antibiotics 44 (91.7 %) 30 (62.5 %) 0.001f
Treated with rifampin 41 (85.4 %) 20 (41.7 %) \0.001f
Rifampin always adequateb 25 15
Rifampin inadequate 16 5
Monotherapy and/or 4 3
Empiric therapyc and/or 6 1
Other reasonsd 7 1
Treatment with high bacterial load 34 (70.8 %) 13 (27.1 %) \0.001f
\2 weeks iv antimicrobial treatment 12 4
No surgical debridement 7 1
No iv and no surgical debridement 15 8
Data are presented as the number (of patients) with the percentage in parenthesis, except where specified otherwise
iv Intravenous
a P values were calculated by v2 except when otherwise specified
b Adequate treatment according to published treatment algorithm [2]
c Rifampin- companion drug with a narrow spectrum against a microorganism with unknown susceptibility
d Rifampin-companion drug with low bioavailability or underdosed
e By Mann–Whitney test
f By Fisher’s exact test
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In an experimental foreignbody infection rat model, after a
7-day-treatment with high-dose rifampin, rifampin-resis-
tant strains appeared between day 8 and 11 at a rate of up to
60% under selective pressure [30]. Thus, there is no doubt
that with increasing use, the fraction of rifampin-resistant
staphylococci will rise [31]. Indeed, in a study involving
patients colonized with S. aureus and treated for tubercu-
losis, rifampin resistance emerged in five of 58 (8.6 %)
patients [21]. Interestingly, subinhibitory concentrations of
ciprofloxacin induce higher frequencies of rifampin-resis-
tant mutants under favourable in vitro conditions [32, 33].
It is therefore important to avoid clinical situations leading
to the emergence or selection of rifampin-resistant staph-
ylococci. Therefore, in our study, we evaluated risk factors
for rifampin resistance in order to develop strategies for the
prevention of rifampin resistance.
Our study showed that rifampin exposure is a risk factor
for the emergence of resistance, if treated inadequately.
The choice of the best combination drug with rifampin is
crucial for the prevention of resistance. John et al. [12]
showed in an animal study that the combination of van-
comycin plus rifampin does not completely prevent the
emergence of rifampin resistance in the case of infection by
high-density MRSA. In contrast, levofloxacin or high-dose
daptomycin combined with rifampin completely prevents
the emergence of rifampin resistance. Sub-inhibitory con-
centrations of fluoroquinolones promote the emergence of
rifampin resistance and, therefore, high doses should be
used in combination with rifampin [12]. In addition, the
results of the susceptibility testing should be known before
treatment is initiated with rifampin. A delay in initiating
rifampin therapy for several days does not lower the cure
rate in patients with PJI treated with debridement and
retention (unpublished cohort data). During the last two
decades, the fraction of fluoroquinolone-resistant staphy-
lococci has been steadily increasing; consequently, fluo-
roquinolone susceptibility of the infecting strain should be
confirmed. In our study, six patients with rifampin-resistant
staphylococcal PJI had been previously treated with a
rifampin combination, with either flucloxacillin or
Table 2 Univariable and multivariable conditional logistic regression analyses of the 96 patients (cases N = 48 and controls N = 48)
Variable Univariable analyses Multivariable analyses
OR (95 % CI) P value OR (95 % CI) P value
Current PJI
Age at hospital admission
\60 years 1 (reference)
60–75 years 1.44 (0.55–3.8) 0.46
75 years 0.51 (0.17–1.6) 0.24
Male gender 3.4 (1.5–8.1) 0.005 3.6 (1.2–11) 0.023
Previous revisions
\3 revisions 1 (reference)
C3 revisions 5.0 (2.1–12) \0.001 4.7 (1.6–14) 0.006
Clinical signs of previous PJI
Sinus tract, wound discharge 2.5 (1.1–6.1) 0.035 2.0 (0.63–6.1) 0.25
Treatment of previous PJI
Treated with antibiotics 6.5 (2.0–21) 0.002
Treated with rifampin 7.8 (2.9–21) \0.001
Rifampin always adequatea 6.6 (2.2–19.4) 0.001 3.2 (0.81–13) 0.096
Rifampin inadequate 10.2 (2.9–36) \0.001 5.4 (1.2–25) 0.029
Rifampin monotherapy 2.9 (0.48–18) 0.25
Empiric therapyb 20 (2.1–185) 0.009
Other reasonsc 21 (2.3–195) 0.007
Treatment with high bacterial load 5.5 (2.4–13) \0.001 4.9 (1.6–15) 0.005
\2 weeks iv treatment 3.5 (1.5–8.1) 0.004
No surgical debridement 3.5 (1.4–8.8) 0.006
CI confidence interval, OR odds ratio
a Adequate treatment according to published treatment algorithm [2]
b Rifampin- companion drug with a narrow spectrum against a microorganism with unknown susceptibility
c Rifampin-companion drug with low bioavailability or underdosed
d P value was calculated by Mann–Whitney test
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clindamycin or ciprofloxacin, without prior knowledge of
the infecting agent. In three other cases, the initial empiric
rifampin combination with flucloxacillin or clindamycin
was given for a few days before unexpected resistance to
these drugs was detected. The statistical analysis showed a
lower odds ratio with rifampin monotherapy than with the
empiric rifampin combination treatment in culture-negative
PJI. This result can be presumably be explained as being
due to a longer exposure to monotherapy in comparison to
when an empiric rifampin combination is used in culture-
negative PJI (52.5 vs. 6.5 days). Of the 48 cases (15 %)
with a rifampin-resistant staphylococcal PJI, seven had no
prior exposure to rifampin. To our knowledge, no in vitro
or in vivo studies have been carried out on the incidence
and terms and conditions of primary resistance in staphy-
lococcal infections. In our study, all but one of the seven
infections with a primary rifampin resistance were caused
by S. epidermidis, a pathogen that mostly presents with
subclinical signs and symptoms that lead to a delay in
diagnosis and probably also to an increased chance of
spontaneous mutations in the rpoB gene. The second
highest association with the emergence of rifampin resis-
tance in our study was a presumed high bacterial density at
the start of rifampin therapy. A high bacterial load was
assumed in the case of missing or inadequate initial sur-
gical debridement (arthroscopy instead of open debride-
ment). In addition, patients treated for \2 weeks with an
intravenous antibiotic as combination partner after the
diagnosis of PJI were also assumed to be at risk because of
the high frequency of single-step mutation (1:108). In an
abscess, the density of staphylococci is at least 108 CFU/
ml; it is therefore reasonable to assume that treating PJI
without debridement surgery or without adequate initial
concomitant high-dose intravenous therapy increases the
risk for emergence of rifampin resistance. Due to the
limited number of patients, we could not separately analyse
whether surgical debridement of infected tissue or high-
dose intravenous antibiotics alone are crucial for preven-
tion of rifampin resistance.
The rationale for multiple previous revisions (C3 times)
being an independent risk factor in our study is not clear. It
is conceivable that the risk for inoculating rifampin-resis-
tant staphylococci from the skin to the prosthesis increases
with each surgical intervention. The increased risk of males
for the emergence of rifampin resistance has no obvious
explanation. We found no correlation with more revisions
and higher age. However, this observation seems not to be
an artifact, since the male predominance was observed in
both centre with the highest number of cases.
This is the first study to analyse risk factors for rifampin
resistance. The strengths of this study are (1) the routine
follow-up visits in all patients with PJI in all study centres,
(2) the prospective data from two centres following their
patients in cohort studies and (3) the standardized surgical
procedures according to an algorithm in most cases. The
study has three limitations. First, it is not a controlled, but
an observational study, and all controls were from one
single centre. However, this one centre prospectively fol-
lows all patients in a cohort study. Therefore, the risk for a
selection bias was lower than the alternative, i.e. to choose
controls from each center. A third limitation is the lack of
MRSA, which precludes a species-specific analysis.
Despite these limitations, this study provides data which
should allow the emergence of rifampin-resistance to be
minimized in the future.
In conclusion, the indication for rifampin combination
therapy needs to be carefully evaluated. In patients with
PJI, rifampin should only be used if indicated according to
published evidence [1–5, 12, 14, 17–20, 33]. Previous
rifampin exposure predisposes to the emergence of rifam-
pin resistance, if treated inadequately. Our data suggest that
extensive surgical debridement and adequate antibiotic
therapy are both crucial for preventing the emergence of
rifampin resistance.
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